글로벌 Anca 혈관염 치료 시장 - 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 Anca 혈관염 치료 시장

anca 혈관염 치료 시장은 2021년에서 2028년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 상기 연구 예측 기간 동안 5.90%의 CAGR로 성장하고 있다고 분석합니다. 최근 개발의 증가와 약물 요법에 대한 FDA 승인은 anca 혈관염 치료 시장 성장을 촉진할 수 있습니다.

예를 들어,

• ChemoCentryx, Inc.의 약물 Avacopan은 FDA에서 anca 혈관염 치료를 위한 신약 신청으로 승인되었습니다. 이 약물은 경구로 투여되며 호중구라고 알려진 파괴적인 염증 세포의 보체 5a 수용체(C5aR)를 차단하도록 제형화되었습니다. NDA에는 약물의 임상 3상 시험이 포함됩니다. 보고서는 이 약물이 부작용이 거의 없이 효과적이라고 제안했습니다.

혈관염은 혈관의 염증이나 부기로 정의됩니다. ANCA 혈관염은 혈관염을 담당하는 일종의 자가면역 질환입니다. ANCA는 항중성구 세포질 자가항체를 의미합니다. 주로 소혈관에 영향을 미치고 ANCA는 중성구라고 하는 백혈구를 공격합니다. 이 중성구는 혈관을 공격하여 혈관이 부어 오르고 염증이 생깁니다. 이 질병의 증상은 ANCA가 혈관을 공격하면 피부 발진이 증상으로 나타나고 신장을 공격하면 신장 손상과 더 많은 증상으로 이어지는 등 감염된 기관에 따라 다릅니다. 주로 50~60세 인구에서 발생하며 남녀 모두에게 흔합니다.  

The rising prevalence of inflammatory disease of blood vessels and increase in geriatric population are other factors for the anca vasculitis treatment market growth. For instance, the prevalence for anca vasculitis is 4.6-18.4 cases per 100,000 worldwide whereas the incidence for the same disease is 1.2 to 2.0 cases per 100,000 people. Complications of the therapies for the ANCA vasculitis treatment such as organ damage, cardiovascular diseases and disabilities. Long term immunosuppressive therapy can affect the fertility rate and bones health which are some of the restraining factor for the anca vasculitis treatment market growth.

Challenging factor for the anca vasculitis treatment market growth is the diagnosis of vasculitis of those patients who are dependent on the dialysis that is dialysis dependent kidney disease because prescribing them toxic immunosuppressive therapy or initiation therapy can be a difficult task for the physician because the patient does not show any response of the treatment.   

This anca vasculitis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the anca vasculitis treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Anca Vasculitis Treatment Market Scope and Market Size

The anca vasculitis treatment market is segmented on the basis of type, diagnosis, treatment type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the anca vasculitis treatment market is segmented into microscopic polyangiitis, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
• On the basis of diagnosis, the anca vasculitis treatment market is segmented into blood test, urine test, X-ray, CT scan, bronchoscopy and biopsy.
• On the basis of treatment type, the anca vasculitis treatment market is segmented into induction therapy, maintenance therapy and other. Induction therapy is further segmented to rituximab (rituxan), cyclophosphamide (cytoxan) and plasmapheresis. Maintenance therapy is further segmented to azathioprine (imuran). Other is further segmented to mycophenolate mofetil (cellCept or myfortic).
• On the basis of route of administration, the anca vasculitis treatment market is segmented into oral and parenteral.
• On the basis of end user, the anca vasculitis treatment market is segmented into government hospitals, hospitals, medical clinics and others.
• On the basis of distribution channel, the anca vasculitis treatment market is segmented into retail store, pharmacy and e-commerce.

Global Anca Vasculitis Treatment Market Country Level Analysis

Global anca vasculitis treatment market is analysed and market size information is provided by country, type, diagnosis, treatment type, route of administration, end user and distribution channel as referenced above.

The countries covered in the anca vasculitis treatment market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts for the largest market share because of increasing prevalence of patients with vasculitis disease, increase healthcare expenditure and rapid awareness among population. Europe is considered as the second largest market share due to increase in advancement in healthcare sector. Asia-Pacific also holds the market share due to increase in geriatric population and government initiatives for the R&D.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The anca vasculitis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to anca vasculitis treatment market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the anca vasculitis treatment market in the growth period.

경쟁 환경 및 글로벌 Anca 혈관염 치료 시장 점유율 분석

anca 혈관염 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 임상 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 글로벌 anca 혈관염 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 anca 혈관염 치료 시장 보고서에 포함된 주요 기업으로는 Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, RNL BIO Co., Ltd., Human Genome Sciences, Inc, Johnson & Johnson Services, Inc., Genentech, Inc., AstraZeneca, Baxter International, Bristol Myers Squibb Company, Celgene Corporation, ChemoCentryx, Daiichi Sankyo, Eli Lilly & Company, Pfizer, Inc. 등이 있으며, 국내 및 글로벌 기업도 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA), 남미에 대해 별도로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.

SKU-60057